![](https://qtxasset.com/quartz/qcloud5/media/image/Stefan%20Photo.jpeg?VersionId=J6OdE_IFialeiGODZ9uKtbc3v4Jw4xo4)
After $185M asset buy, Merz Therapeutics plots US workforce expansion as CEO eyes more deals
Freshly equipped with two approved meds from Acorda Therapeutics, Frankfurt, Germany’s Merz Therapeutics is kicking its specialty neurology ambitions into high gear. Wednesday, the drugmaker said it closed a $185 million deal to acquire Acorda Therapeutics …